Latest Ophthalmology News

Page 1 of 3
Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.
Ada Torres
Ada Torres
28 May 2026
Invion Limited has partnered with South Korea's SANGMYUNG Innovation to explore its Photosoft™ photodynamic therapy for wet age-related macular degeneration, addressing a large unmet medical need in ophthalmology.
Ada Torres
Ada Torres
19 May 2026
PYC Therapeutics presented Phase 1/2 data at ARVO 2026 showing encouraging safety and efficacy signals for its RNA therapies targeting rare genetic eye diseases Retinitis Pigmentosa type 11 and Autosomal Dominant Optic Atrophy.
Ada Torres
Ada Torres
4 May 2026
Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.
Ada Torres
Ada Torres
29 Apr 2026
PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.
Ada Torres
Ada Torres
28 Apr 2026
Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.
Ada Torres
Ada Torres
28 Apr 2026
Cambium Bio has secured FDA confirmation that a single pivotal Phase 3 trial plus confirmatory evidence will suffice for Biologics License Application submission for Elate Ocular, significantly reducing development expenses and accelerating the pathway to market.
Ada Torres
Ada Torres
23 Apr 2026
Opthea Limited reports a striking turnaround with a $339.9 million profit for H1 2026, driven by a strategic refocus on developing OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The company plans a rebrand and ASX reinstatement as it charts a new course in rare respiratory health.
Ada Torres
Ada Torres
2 Mar 2026
Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.
Ada Torres
Ada Torres
20 Feb 2026
Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.
Ada Torres
Ada Torres
29 Jan 2026
Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.
Ada Torres
Ada Torres
23 Jan 2026
Cambium Bio has locked in a A$2.4 million strategic investment from Zheng Yang Biomedical Technology, reinforcing its push into pivotal Phase 3 trials for its dry eye disease treatment.
Ada Torres
Ada Torres
20 Jan 2026